The approval is based on data from a late-stage clinical trial that enrolled more than 40,000 adults aged 50 and older. In this trial, Moderna’s mRNA flu shot demonstrated a 26.6 percent higher effectiveness compared with a licensed standard-dose flu vaccine. The results suggest the mRNA platform could offer improved protection relative to traditional vaccines for this age group, which is historically at greater risk from influenza complications.
Regulators emphasized the importance of real-world performance as the vaccine rolls out in the market. The approval applies to adults 50 and older, a demographic frequently targeted for annual flu vaccination due to elevated vulnerability to severe illness. The FDA’s decision could influence future vaccine design, potentially accelerating development of additional mRNA-based vaccines for infectious diseases beyond influenza.
Health authorities in Canada are also reviewing the U.S. decision as Health Canada considers its own authorization for Moderna’s mRNA flu shot. The ongoing deliberations in Canada will determine whether the vaccine becomes available to Canadian adults later in the season, subject to regulatory review and guidance.
Moderna’s mRNA flu vaccine represents a departure from conventional flu vaccines that rely on traditional vaccine platforms. If adopted in broader immunization programs, it may affect vaccination schedules, supply chains, and strategies for addressing influenza in upcoming seasons. Public health experts will closely monitor post-licensure data to assess long-term safety, effectiveness, and any implications for pediatric use or broader age groups.
